Articles related to PRECISION MEDICINE

The prevalence of HRR deficiencies has been found to be as high as 20% to 30% in patients with mCRPC, a significantly higher rate than that in patients with localized disease.

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.

Although genomic classifier tests for prostate cancer show promise, a systematic review of 22 studies reveals marked differences between observational and trial data in how these tests influence risk stratification and treatment selection.

Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.

The multidisciplinary guidelines introduce blood-based biomarkers as key diagnostic tools, potentially reducing unnecessary CT scans while improving outcome predictions.

Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.